OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zain on Investigational Approaches in Peripheral T-Cell Lymphoma

August 16th 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

Dr. Abraham on Improving Access to Therapy With Biosimilars

August 16th 2019

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars.

Dr. Martin on Ibrutinib/Palbociclib Combo in Ibrutinib-Resistant MCL

August 16th 2019

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

Dr. Manji on Treatment for BRAF-Mutant CRC

August 16th 2019

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

August 16th 2019

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer

August 16th 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.

Dr. Saba on Investigational Deintensification Approaches in HPV-Related HNSCC

August 15th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.

Dr. Pullarkat on Treatment Strategies in Transplant Ineligible ALL

August 15th 2019

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

Dr. Thiel on Surgical Advances for RCC

August 15th 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the advancements in surgical techniques for renal cell carcinoma.

Dr. Mizrahi on Encouraging Trial Findings in mCRC

August 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Dr. Tan on Imaging Modalities in Prostate Cancer

August 15th 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.

Dr. Kolberg on the Cardiac Safety of ABP 980 in HER2-Positive Breast Cancer

August 15th 2019

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the safety profile of ABP 980 (Kanjinti; trastuzumab-anns).

Dr. Patel on Ongoing Immunotherapy Research for NSCLC

August 15th 2019

Manish R. Patel, DO, discusses current questions and research regarding immunotherapy in non–small cell lung cancer.

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

August 14th 2019

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Dr. Castillo on Emerging Treatment Approaches in Waldenstrom Macroglobulinemia

August 14th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, highlights ongoing research with emerging treatment approaches in Waldenström macroglobulinemia.

Dr. Iveson on the IDEA Collaboration in CRC

August 14th 2019

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Dr. Esteva on Trastuzumab Biosimilar in Breast Cancer

August 14th 2019

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, director, Breast Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the use of trastuzumab biosimilars in the treatment of patients with breast cancer.

Dr. Gogineni on De-Escalation Strategies in HER2+ Breast Cancer

August 14th 2019

Keerthi Gogineni, MD, MSHP, an assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses de-escalation strategies in HER2-positive breast cancer.

Dr. Snyder on Mainstays of Treatment in Polycythemia Vera

August 14th 2019

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

Dr. Rule on the Treatment Paradigm in MCL

August 14th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the treatment paradigm in mantle cell lymphoma (MCL).